Bio-rad Laboratories, INC Form 4 insider transactions

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.

Director Allison Schwartz reports acquisition and disposal of Bio-Rad Laboratories Class A common stock related to vesting of restricted stock units.

Director Allison Schwartz reports receiving 57 shares of Bio-Rad B Common Stock on August 26, 2024.

Steven Schwartz, a director at Bio-Rad Laboratories, filed a Form 4 detailing changes in his beneficial ownership of company stock due to gift transactions.

Norman Schwartz, CEO of Bio-Rad Laboratories, reports a change in his beneficial ownership of company stock due to a gift.

Alice N. Schwartz, a Director Emeritus at Bio-Rad Laboratories, filed a Form 4 detailing changes in her beneficial ownership of the company's stock due to a gift.

Eva Anette Engelhardt, EVP and President of CDG at Bio-Rad Laboratories, acquired 983 restricted stock units on July 25, 2024, vesting over four years.

Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, sold 369 shares of Bio-Rad A Common Stock at a price of $281.9064 on June 13, 2024.

Director Steven Schwartz reported selling 320 shares of Bio-Rad Laboratories Class A common stock at $463.86 per share on May 3, 2023.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent tax withholding.

Roop Kalyan Lakkaraju, EVP and CFO of Bio-Rad Laboratories, reports the acquisition of 4,311 restricted stock units.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 744 restricted stock units on April 24, 2024, which vest over four years.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, acquired 5,891 non-qualified stock options on March 8, 2024.

Simon May, EVP and President of Life Science Group at Bio-Rad Laboratories, acquired 3,535 non-qualified stock options on March 8, 2024.

EVP of Global Human Resources at Bio-Rad Laboratories, Colleen Corey, reports the acquisition of stock options.

Timothy S. Ernst, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 2,357 non-qualified stock options on March 8, 2024.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reports acquisition of shares through employee stock purchase plan and grant of stock options.

Norman Schwartz, CEO of Bio-Rad Laboratories, reports the acquisition of stock options and changes in beneficial ownership of Bio-Rad common stock.

Michael Crowley, EVP at Bio-Rad Laboratories, reports acquisition of stock options.

EVP, General Counsel & Secretary of Bio-Rad Laboratories, Timothy S. Ernst, reports the exercise of stock options and subsequent sale of shares on February 28, 2024.

Michael Crowley, EVP at Bio-Rad Laboratories, exercised stock options and sold shares on February 27, 2024.